Phase 1 multicenter, dose-expansion study of ARX788 as monotherapy in HER2-positive advanced gastric and gastroesophageal junction adenocarcinoma

Yang Zhang(Guangdong Testing Institute for Product Quality Supervision), Rui‐Hua Xu(Sun Yat-sen University), Gao-Zhun Xiong, Qi Zhao(Academy of Medical Sciences), Ao Shen(Sun Yat-sen University), Yanqiao Zhang(Harbin Medical University), Miao‐Zhen Qiu(Sun Yat-sen University), Xuejun Liang, Tao� Zhang(Ningbo University), Xiaoli Wei(Anhui Medical University), Jufeng Wang(Henan Cancer Hospital), Yanping Ji, Gang Xia(World Vision), Hongyun Zhao(Sun Yat-sen University), Xianglin Yuan(Tongji University), De‐Shen Wang(Sun Yat-sen University)
Cell Reports Medicine
November 1, 2022
Cited by 51


Related Papers